Stanford Researchers Developed Bladder Cancer Urine Test
A new diagnostic test identified 95 percent of bladder cancer cases in a recent study.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Would you trust a new urine-based test to guide your cancer diagnosis and treatment decisions?
Stanford University researchers have developed a novel urine test called uRARE-seq that identifies bladder cancer by measuring RNA messages from tumor cells. The test also assists in determining how patients might respond to BCG immunotherapy.
Why it matters
Current diagnostic methods for bladder cancer can miss approximately 30 percent of cases, necessitating more accurate tools. This test could enable earlier detection and improved treatment selection for the 85,000 Americans diagnosed annually.
In a study of 700 urine samples, the test achieved 95 percent sensitivity for cancer detection and 90 percent specificity in identifying healthy participants. These metrics reflect performance compared to existing standards that often miss 30 percent of diagnoses.
The players
Stanford University
This private research university located in California is a leading center for academic innovation and medical research.
Nature Medicine
This is a peer-reviewed monthly medical journal that publishes research on clinical and translational medicine.
The details
The uRARE-seq test works by analyzing specific RNA messages released by tumor cells into a patient's urine. Researchers indicated that the method could potentially be adapted in the future to detect other malignancies, including prostate and kidney cancers.
Timeline
October 2, 2026: The study was published in the journal Nature Medicine.
Health Landscape
This study advances the field of non-invasive liquid biopsies by demonstrating that RNA markers in urine can reliably identify bladder malignancies. It reflects a broader shift toward using molecular analysis to catch cancers at earlier, more treatable stages.
If validated for clinical use, this test could provide a less invasive diagnostic option compared to current standard procedures. Patients may benefit from faster results and more personalized treatment plans, specifically regarding BCG immunotherapy effectiveness.
The takeaway
This breakthrough highlights the potential of liquid biopsies to transform standard oncological diagnostics. Future clinical trials will determine if this technology can effectively replace current screening methods in community healthcare settings.
Further reading
For more information on current screening advancements, visit the Cancer section.
More information
Read the complete findings of the Nature Medicine study for detailed technical specifications.
Live Poll
Would you trust a new urine-based test to guide your cancer diagnosis and treatment decisions?
